Has Edward Karpman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $403,905 in general payments to Edward Karpman, MD across 793 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edward Karpman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edward Karpman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edward Karpman, MD

Urology · Mountain View, CANPI 1851349609

Payments from drug & device makers

$403,905in general payments, 2019–2025

Across 793 payments — averaging $509.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$221K
Coloplast$161K
Innovation Technologies Inc$7K
Axonics, Inc.$2K
Antares Pharma, Inc.$2K
Endo Pharmaceuticals Inc.$2K
plus $8K from 42 others

$7,500in research payments, 2019–2025

Across 1 payment — averaging $7500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Innovation Technologies Inc$8K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	138	$221,154
Coloplast	181	$161,397
Innovation Technologies Inc	10	$7,156
Axonics, Inc.	25	$2,467
Antares Pharma, Inc.	127	$2,139
Endo Pharmaceuticals Inc.	57	$1,975
Sumitomo Pharma America, Inc.	36	$1,020
Noah Medical Corporation	1	$1,000
Astellas Pharma US Inc	37	$672
Urovant Sciences Inc	25	$602
AbbVie(2 entities)	22	$534
Procept Biorobotics Corporation	9	$398
Richard Wolf Medical Instruments Corp.	1	$350
Halozyme Inc	22	$295
Pfizer	16	$273
Johnson & Johnson	19	$252
Dendreon Pharmaceuticals LLC	8	$247
Medtronic	4	$231
Valencia Technologies Corporation	2	$185
Agiliti Surgical, Inc.	2	$151
Amgen	5	$143
EDAP Technomed Inc	1	$125
Progenics Pharmaceuticals, Inc.	6	$123
Rigicon,inc.	1	$107
Endo USA, Inc.	4	$84
Contura, Inc.	1	$83
Hollister Incorporated	4	$83
Trisalus Life Sciences, Inc.	1	$69
Organogenesis Inc.	1	$43
Myriad Genetic Laboratories, Inc.	2	$42
Accord Healthcare, Inc.	2	$41
Bayer	2	$40
Ferring Pharmaceuticals Inc.	2	$39
Biotissue Holdings Inc.	2	$38
Teleflex LLC	1	$37
Novartis	1	$34
Merck	1	$33
180 Medical, Inc.	2	$29
Urogen Pharma, Inc.	2	$27
Laborie Medical Technologies Corp.	2	$25
Therapeuticsmd, Inc.	1	$24
Olympus America Inc.	1	$23
Tolmar, Inc.	1	$23
AstraZeneca	1	$23
Verity Pharmaceuticals Inc.	1	$20
Clarus Therapeutics Inc.	1	$16
SRS Medical Systems, Inc.	1	$15
Photocure Inc	1	$15

How this compares

$403,905 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$944,658

Medicare patients

594

Services billed

160,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Mountain View

Edward UchioOrange$21.1M
Stephen FreedlandWest Hollywood$16.7M
Alec KooTorrance$7.4M
Karim ChamieLos Angeles$4.3M
Ralph ClaymanOrange$3.9M
Siamak DaneshmandLos Angeles$3.5M
Arnold ChinLos Angeles$3.5M
Roger LiLoma Linda$2.3M
John KowalczykLos Angeles$1.8M
Arie BelldegrunLos Angeles$1.8M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →